Fractyl raises series E funding of USD 55 million for diabetes cure
By Nikita Chaurasia  Date: 2020-08-10

Fractyl raises series E funding of USD 55 million for diabetes cure

Fractyl Laboratories raised series E funding of USD 55 million to continue financing the pivotal clinical trial of its potential non-surgical, non-drug treatment for Type 2 diabetes.

As per the trusted sources, the capital will be invested on mass-based startup’s Revita T2Di pivotal clinical trial of Revita DMR. Revita is observing the effect of Fractyl’s Revita DMR treatment on insulin requirements and glycemic control.

Reportedly, the funding round was led by the new investor named Taiwania Capital Management Corporation. The financing also involved the existing investors like Emergent Medical Partners, Bessemer Venture Partners, Domain Associates, True Ventures, General Catalyst, Mithril Capital Management, and GV. The funding round included first time commitments from CDIB Venture Capital Corp., Catalio Capital Management, and YJ Capital.

Michael Huang, managing partner at Taiwania Capital Management Corporation, has reportedly stated that type 2 diabetes and NAFLD/NASH have adverse effects on people’s health across the world and account for majority global healthcare expenditure. He further added that Fractyl has carried out studies which reveal Revita’s potential to enhance the outcomes of the treatment for type 2 diabetes.

Fractyl’s co-founder and CEO Harith Rajagopalan states that Fractyl’s mission is to treat diabetes type 2 in a better way by addressing its root cause, that can reverse the disease process rather than managing its symptoms. He said that they now have database of hundreds of patients who suffered from type 2 diabetes and have shown long term benefits of a single Revita treatment.

Rajagopalan added that he welcomes the new investors and the continued support of the returning investors who saw that they have the potential to redefine the treatment for metabolic diseases like NAFLD/NASH and type 2 diabetes.

The company is looking forward to beginning with their pivotal U.S. clinical trial later this year.

Source credits-

https://www.massdevice.com/fractyl-adds-55m-for-type-2-diabetes-pivotal-trial/

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Fragomen acquires SimpleCitizen to reinforce its immigration services
Fragomen acquires SimpleCitizen to reinforce its immigration services
By Nikita Chaurasia

In a recent turn of events, Fragomen, Del Rey, Bernsen & Loewy, LLP, a leading corporate immigration law company has reportedly joined hands with SimpleCitizen Inc. to form Fragomen Technologies Inc., a new subsidiary which will provide a combina...

Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
By Nikita Chaurasia

Solar project development and asset management major, Nautilus Solar Energy LLC, has reportedly announced its acquisition of two solar portfolios in Rhode Island and Oregon amounting to a total of nearly 17 MW from leading solar energy developer, Pin...

Locate Bio obtains multiple late stage orthobiologics assets from RCSI
Locate Bio obtains multiple late stage orthobiologics assets from RCSI
By Nikita Chaurasia

Regenerative medicine major, Locate Bio, has reportedly announced its in-licensing of several late stage orthobiologics assets from the RCSI University of Medicine and Health Sciences. Sources state that the technologies created by the RCSI Tissue E...

Roche acquires Inflazome to gain control over inflammatory treatments
Roche acquires Inflazome to gain control over inflammatory treatments
By Nikita Chaurasia

In a recent turn of events, Swiss healthcare giant, F. Hoffmann-La Roche AG has reportedly acquired an Irish biotech firm Inflazome Ltd. for approximately USD 451 million (€380 million). As per the agreement, Roche will acquire complete rights ...

Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
By Nikita Chaurasia

Innovent Biologics Inc., in collaboration with American pharmaceutical giant Eli Lilly and Company, have reportedly announced that the biomarker results of ORIENT-11 trials which were displayed during a mini verbal presentation at ESMO (European Soci...